Development of SGLT1 and SGLT2 inhibitors

2018/07/20 by Timo Rieg, Volker Vallon · 27 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Diabetes Treatment and Management #Pancreatic function and diabetes #Metabolism, Diabetes, and Cancer

paper · pdf · doi:10.1007/s00125-018-4654-7

Cited by

• Glucose transporters in pancreatic islets
• Reshaping the Treatment Landscape of a Galactose Metabolism Disorder
• Role of TRPC6 in Progression of Diabetic Kidney Disease. [europepmc]
• Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants. [europepmc]
• Progression of diabetic kidney disease in T2DN rats. [europepmc]
• Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease? [europepmc]
• Glucose transporters in the kidney in health and disease. [europepmc]
• The tubular hypothesis of nephron filtration and diabetic kidney disease. [europepmc]
• Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. [europepmc]
• Glucose transporters in pancreatic islets. [europepmc]
• SGLT2i: beyond the glucose-lowering effect. [europepmc]
• SGLT2 and cancer. [europepmc]
• Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development. [europepmc]
• Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells. [europepmc]
• The Potential Role of Flavonoids in Ameliorating Diabetic Cardiomyopathy via Alleviation of Cardiac Oxidative Stress, Inflammation and Apoptosis. [europepmc]
• Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges. [europepmc]
• 100 years of insulin: celebrating the past, present and future of diabetes therapy. [europepmc]
• Mechanisms of Glucose Absorption in the Small Intestine in Health and Metabolic Diseases and Their Role in Appetite Regulation. [europepmc]
• Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. [europepmc]
• Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes. [europepmc]
• SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na + transport in Dahl SS rats. [europepmc]
• SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma. [europepmc]
• Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications. [europepmc]
• Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control. [europepmc]
• Central role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy. [europepmc]
• Immunomodulatory Effects of SGLT2 Inhibitors-Targeting Inflammation and Oxidative Stress in Aging. [europepmc]
• View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences. [europepmc]